- Home
- LRE vs LGVN Comparison
LRE vs LGVN Comparison
Compare LRE & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | LGVN |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 17.6M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRE | LGVN |
|---|---|---|
| Price | $1.29 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 7.7K | ★ 426.5K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.52 |
| 52 Week High | $2.97 | $2.24 |
Technical Indicators
Market Signals| Indicator | LRE | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 31.31 |
| Support Level | $1.26 | $0.52 |
| Resistance Level | $1.45 | $0.57 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 16.22 | 0.21 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.